Blood Pressure Medication Recalled Over Cancer-Causing Chemical Concerns
Teva Pharmaceuticals has issued a voluntary recall for more than 580,000 bottles of blood pressure medication due to safety concerns. The recall affects prazosin hydrochloride capsules, which have been found to contain elevated levels of a cancer-causing chemical.
Details of the Recall
The U.S. Food and Drug Administration (FDA) classified this recall as a Class II risk. This classification indicates that using or being exposed to the affected product may result in temporary or medically reversible adverse health effects. The likelihood of serious health consequences is considered low.
Identified Risks
The primary concern is the presence of nitrosamine impurities, specifically a chemical known as No-nitroso Prazosin impurity C. These compounds have been linked to significant health risks, prompting the FDA’s action. Prazosin is typically prescribed for managing high blood pressure and is also utilized to alleviate nightmares associated with post-traumatic stress disorder (PTSD).
Recalled Products Overview
- Total bottles recalled: Over 580,000
- Breakdown:
- 1 mg bottles: 181,659
- 2 mg bottles: 291,512
- 5 mg bottles: 107,673
- Capsules per bottle: Up to 1,000
Next Steps for Consumers
The FDA did not provide specific instructions for what customers should do with the recalled bottles. Consumers are advised to stay informed through official channels for further guidance regarding the recall.
Conclusion
This recall underscores the importance of monitoring medications for safety issues. Patients taking prazosin should consult with their healthcare providers to discuss alternatives and ensure their treatment continues effectively and safely.
